Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single Doses Subcutaneous Administration of TEV-48125 (Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single Doses Subcutaneous Administration of TEV-48125 (Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

Most Recent Events

  • 06 Jun 2021 Results of HV Study NCT02673567 ( n = 64) and the Phase 2 PTH Study NCT03347188 ( n = 87), assessing evaluation of the correlations between pretreatment plasma CGRP levels, disease characteristics and fremanezumab treatment response in patients with posttraumatic headache, presented at the 63rd Annual Scientific Meeting of the American Headache Society
  • 05 Sep 2017 According to a Teva Pharmaceutical media release, data will be presented at at the 18th Congress of the International Headache Society (IHC).
  • 20 Apr 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top